Physician profile
Vishad Sheth
NPI 1538572219
$2,115.59
in general payments reported to CMS, 2019-2025
25 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.88 · 2022: $388 · 2023: $158 · 2024: $332 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902 · Travel and Lodging: $573 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.55 |
| Travel and Lodging | $572.69 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $572.69 | 2025 | Vasoview Hemopro 2 |
| Glaxosmithkline, LLC. | $237.08 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Verathon INC. | $200.00 | 2025 | Bronchoscope |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.23 | 2022-2023 | Lifevest |
| Ambu INC. | $123.32 | 2025 | |
| Amgen INC. | $117.00 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $103.88 | 2021-2023 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $81.07 | 2024-2025 | Glassia |
| Merck Sharp & Dohme LLC | $57.10 | 2022-2024 | Zerbaxa, Dificid, Recarbrio |
| Inquis Medical, INC. | $54.55 | 2024 | |
| Genzyme Corporation | $48.56 | 2022-2024 | |
| Mindray Ds USA, INC. | $47.49 | 2024 | Te7 Max, Te X |
| Boston Scientific Corporation | $45.70 | 2022-2024 | Exalt Model D |
| La Jolla Pharmaceutical Company | $39.26 | 2025 | |
| Inspire Medical Systems, INC. | $33.55 | 2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $32.22 | 2022 | |
| Mylan Specialty L.P. | $31.32 | 2022 | |
| Medtronic, INC. | $26.19 | 2021 | |
| Baxter Healthcare | $23.91 | 2022 | |
| Viatris Specialty LLC | $20.51 | 2025 | Yupelri |
| Philips North America LLC | $20.00 | 2023 | |
| Pfizer INC. | $19.00 | 2024 | |
| Insmed, INC. | $18.33 | 2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishad Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.